News

Risk of Hypoparathyroidism Seen After Lymph Node Removal

Central lymph node dissection, or the removal of lymph nodes in the neck, increases the risk of both temporary and permanent post-surgical hypoparathyroidism in people with thyroid cancer who undergo surgery to remove the thyroid gland, a 10-year French study reports Also, lateral lymph node dissection along with total…

Hypoparathyroidism Tied to Rare Heart Muscle Disease in Woman

Hypoparathyroidism was associated with hypertrophic cardiomyopathy — heart disease marked by thickened heart muscle, so that the heart pumps blood less effectively — in a 73-year-old woman, according to a case study. This rare finding was reported in “Hypertrophic cardiomyopathy in a patient with secondary hypoparathyroidism:…

Ascendis Seeks EMA Approval of TransCon PTH for Adults in EU

Ascendis Pharma is seeking approval of its treatment candidate TransCon PTH for adults with hypoparathyroidism in the European Union, the company has announced. The request, submitted as a marketing authorization application (MAA) to the European Medicines Agency (EMA), follows a similar application submitted in September to the U.S.

Survey Assesses Expert Practices for Monitoring Hypoparathyroidism

Most experts report similar practices for how they monitor blood and urine tests in people with chronic hypoparathyroidism, but monitoring practices for disease complications like kidney or bone problems are more variable, a new study reports. “While [blood] and urine measurements are completed consistent with published guidelines and consensus…

Natpara Cuts Risk of Chronic Kidney Disease in Half: Study

People with hypoparathyroidism who are on replacement therapy with Natpara, a version of the parathyroid hormone (PTH), are about half as likely to develop chronic kidney disease than patients who don’t receive the therapy, a study found. The study, “The risk of chronic kidney disease development in…

Trial Testing MBX 2109 in Healthy Volunteers Advances to Part 2

A Phase 1 clinical trial evaluating the safety and pharmacological properties of MBX 2109 — MBX Biosciences’ investigational hormone replacement therapy for people with hypoparathyroidism — in healthy volunteers has moved to its second part. This portion, which will test multiple MBX 2109 doses, follows the successful completion…